More precise data. Better patient management.

The DecisionDx-Melanoma gene expression profiling (GEP) test can help empower you to make more informed, more accurate decisions and ultimately improve patient care. 

The only GEP test associated with improved patient survival

DecisionDx-Melanoma is supported by over 50 peer-reviewed publications and provides personalized results for patients with stage I-III cutaneous melanoma, helping guide risk-aligned management decisions. By combining tumor biology with traditional clinicopathological features, the test offers two critical applications for surgeons:

  1. Preoperative Decision-Making:
    Is it likely that my patient can safely forego a sentinel lymph node biopsy (SLNB)?

  2. Postoperative Management:
    How can I better manage my node-negative patients?

The clinical utility of DecisionDx-Melanoma

Learn more about how to incorporate DecisionDx-Melanoma into your surgical practice to personalize patient care.

   

I want to connect to a representative

Improve your pre-operative surgical decisions with DecisionDx-Melanoma

DecisionDx-Melanoma offers precise risk assessments, helping you identify patients who may need a sentinel lymph node biopsy (SLNB) and those who can safely forgo it.

A recent prospective, multi-center study showed that DecisionDx-Melanoma can provide increased confidence that patients can safely forgo the procedure.3   

  • No low-risk (Class 1A) patients have experienced a recurrence at 2-years median follow-up.  
  • No patient with a predicted i31-SLNB risk below 5% had a positive node after undergoing SLNB.

View study

In an independent performance cohort, DecisionDx-Melanoma outperformed AJCCv8 in identifying patients who should undergo an SLNB4

  • Regardless of T stage, ~1/3 of patients who received a high-risk test result (>10% risk) had a positive node
    • In T1-T2 tumors, 33% had a +SLN (10/30)​
    • In T3-T4 tumors, 31% had a +SLN (20/64)

View study

The SLNB procedure provides valuable prognostic information in the right patient, but has limitations

What does this mean? 

  • High-risk melanoma patients may be overlooked. Even if a patient is node-negative, they could still face melanoma recurrence and/or metastasis. This highlights the need for additional prognostic tools, such as DecisionDx-Melanoma.

  • Not all patients require the SLNB procedure. By using DecisionDx-Melanoma, you can potentially reduce unnecessary procedures, lower overall healthcare costs, and focus resources on higher risk patients.

Enhance post-operative care with a personalized risk assessment

A recent independent, multi-center study analyzed the utility of routine imaging to detect metastases in SLN-negative patients with a high risk DecisionDx-Melanoma result. This analysis of clinically tested patients was performed at three NCI-designated cancer centers (Northwestern University, Cleveland Clinic, and Oregon Health & Science University), and included patients with confirmed melanoma diagnosis and negative SLNB.

The experimental group (n=307) included the high risk DecisionDx-Melanoma patients, and physicians used the results to guide their melanoma management. The control group (n=327) consisted of patients who did not receive DecisionDx-Melanoma testing, and their management was based on symptoms or exam findings.

The results? Patients who received routine imaging after high-risk GEP test scores had an earlier recurrence diagnosis with lower tumor burden, which was associated with better clinical outcomes.5

DecisionDx-Melanama provides individualized risk stratification and can predict survival outcomes

In the largest real-world study of GEP testing in melanoma, the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program Registries showed that DecisionDx-Melanoma testing is linked to lower melanoma-specific and overall mortality compared to untested patients. The test can provide significant, independent risk stratification beyond AJCC8 staging, aiding in personalized patient management6  

   

I want to connect with a representative
29% Lower 3-year melanoma-specific mortality rate in patients clinically tested vs. untested 17% Lower 3-year overall mortality rate in patients clinically tested vs. untested

Hear from an expert: How Mark Gimbel, MD uses DecisionDx-Melanoma to personalize care

  • Dr. Gimbel, a surgical oncologist specializing in melanoma, discusses how he integrates DecisionDx-Melanoma into his daily practice. Watch the video to see how an expert uses this powerful prognostic tool to guide treatment decisions and enhance patient care at every step in their journey.

The leader in melanoma prognostic testing with independent, robust validation and real-world results

150,000+

patients with a clinical DecisionDx-Melanoma order from ~13,000 clinicians

50+ 

peer reviewed, published studies inlcuding prospective studies and three meta-analyses

Medicare+

covered by Medicare and multiple private insurers with an industry-leading patient assistance program

*Numbers as of February 2024

Ready to enhance your decision making and improve patient outcomes?

How to order
Connect with a rep
Join our email list

References

  1. Guenther et al 2024, Oral poster presentation, Soc Surg Onc, March 2024.
  2. Yamamoto et al, CMRO. 2023.
  3. Guenther, JM, et al. Society of Surgical Oncology SSO 2024 Annual Meeting. Ann Surg Oncol. 31 (Suppl 1), S32 (2024).
  4. Kriza et al., World J Surg Oncol. 2024. 
  5. Dhillon et al., Archives of Derm Research. 2023.
  6. Bailey et al. JCO PO. 2023